The title compound, C16H11F4N3O2, was synthesized and structurally characterized by elemental analysis, IR, MS, 1 H-NMR and single-crystal X-ray diffraction. This compound has a pyrazolo[1,5-a]pyrimidine skeleton, and...The title compound, C16H11F4N3O2, was synthesized and structurally characterized by elemental analysis, IR, MS, 1 H-NMR and single-crystal X-ray diffraction. This compound has a pyrazolo[1,5-a]pyrimidine skeleton, and it crystallizes in monoclinic system, space group P21/c with a = 20.8547(12), b = 20.5558(10), c = 7.1575(4) ?, β = 96.610(5)°, V = 3047.9(3) ?3, Z = 4, Dc = 1.540 g·cm-3, F(000) = 1440, μ(Mo Kα) = 0.14 mm-1, R = 0.0546 and wR = 0.1276 for 5370 reflections with I > 2σ(I). In addition, biological activity determination results indicated that the title compound exhibited poor inhibitory activity on MKN45 and H460 cancer cell lines.展开更多
基金Supported by the Key Scientific Research Project of Education Department of Shaanxi Province (17JS027)the team of syngas catalytic conversion of Shaanxi university of Technology。
文摘The title compound, C16H11F4N3O2, was synthesized and structurally characterized by elemental analysis, IR, MS, 1 H-NMR and single-crystal X-ray diffraction. This compound has a pyrazolo[1,5-a]pyrimidine skeleton, and it crystallizes in monoclinic system, space group P21/c with a = 20.8547(12), b = 20.5558(10), c = 7.1575(4) ?, β = 96.610(5)°, V = 3047.9(3) ?3, Z = 4, Dc = 1.540 g·cm-3, F(000) = 1440, μ(Mo Kα) = 0.14 mm-1, R = 0.0546 and wR = 0.1276 for 5370 reflections with I > 2σ(I). In addition, biological activity determination results indicated that the title compound exhibited poor inhibitory activity on MKN45 and H460 cancer cell lines.
